For years, researchers knew different factors were causing lung cancer tumors to grow, but they didn't know why, or how to interrupt the process. Then, a group of lung cancer researchers discovered the EGFR biomarker, which opened the door for targeted therapies that were easier to take, more effective, and led to better patient outcomes than anything used before. Take this opportunity to hear from someone who had a part in discovering the first lung cancer biomarker. Learn more about the EGFR biomarker from Dr. Carbone – important information that every EGFR patient needs to know.

Guest

Dr. David Carbone is a lung cancer clinician, researcher and specialist at The Ohio State University Comprehensive Cancer Center. He’s been working on developing treatments for lung cancer for years, and played an important role in discovering the first targeted therapy aimed at the EGFR biomarker.

Transcript | Video Podcast